Activities of the triazole derivative SCH 56592 (Posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 1, 2000, Pages 150-155

  Molina, Judith ^a,b   Martins Filho, Olindo ^a   Brener, Zigman ^a   Romanha, Alvaro J ^a   Loebenberg, David ^d   Urbina, Julio A ^c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^c INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; ANTIFUNGAL AGENT; BENZNIDAZOLE; CYCLOPHOSPHAMIDE; KETOCONAZOLE; NIFURTIMOX; NITROFURAN DERIVATIVE; NITROIMIDAZOLE DERIVATIVE; POSACONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHRONICITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; FEMALE; IMMUNOCOMPETENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; SURVIVAL RATE; TRYPANOSOMA CRUZI;

EID: 0033987127     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.1.150-155.2000     Document Type: Article

References (36)

1. Araújo, M. S. S., J. Molina, M. E. S. Pereira, and Z. Brener. 1996. Combination of drugs in the treatment of experimental Trypanosoma cruzi infection. Mem. Inst. Oswaldo Cruz 91(Suppl. 1):315.
2. Brener, Z. 1992. Trypanosoma cruzi: taxonomy, morphology and life cycle, p. 13-29. In S. Wendel, Z. Brener, M. E. Camargo, and A. Rassi (ed.), Chagas disease (American trypanosomiasis): its impact on tranfusion and clinical medicine. ISBT Brazil'92, São Paulo, Brazil.
3. Brener, Z., J. R. Cançado, L. M. Galvāo, Z. M. P. da Luz, L. D. S. Filardi, M. E. S. Pereira, L. M. T. Santos, and C. B. Cançado. 1993. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem. Inst. Oswaldo Cruz 88:149-153.
4. Brener, Z., and R. T. Gazzinelli. 1997. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int. Arch. Allergy Immunol. 114:103-110.
5. Buckner, F. S., A. J. Wilson, T. C. White, and W. C. Van Voorhis. 1998. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob. Agents Chemother. 42:3245-3250.
6. Connolly, P., J. Wheat, C. Schnizlein-Nick, M. Durkin, S. Kohler, M. Smedema, J. Goldberg, E. Brizendine, and D. Loebenberg. 1999. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother. 43:322-328.
7. Croft, S. L., J. A. Urbina, and R. Brun. 1997. Chemotherapy of human leishmaniasis and trypanosomiasis, p. 245-257. In G. Hide, J. C. Mottram, G. H. Coombs, and P. H. Holmes (ed.), Trypanomiasis and leishmaniasis. CAB International, London, England.
8. de Castro, S. L. 1993. The challenge of Chagas disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi. Acta Trop. 53:83-98.
9. Ferreira, M. S., S. A. Nishioka, A. Rocha, and A. M. Silva. 1997. Doença de Chagas e imunosupressão, p. 365-379. In J. C. Pinto Dias and J. Rodrigues Coura (ed.), Clínica y terapêutica de doença de Chagas. Editora Fiocruz, Rio de Janeiro, Brazil.
10. Filardi, L. S., and Z. Brener. 1987. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used in Chagas disease. Trans. R. Soc. Trop. Med. Hyg. 81:755-759.
11. Hudson, L., F. Grover, W. E. Gutteridge, R. A. Klein, W. Peters, R. A. Neal, M. A. Miles, M. T. Scott, R. Nourish, and B. P. Ager. 1983. Suggested guidelines for work with live Trypanosoma cruzi. Trans. R. Soc. Trop. Med. Hyg. 77:416-419.
12. Law, D., C. B. Moore, and D. W. Denning. 1997. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob. Agents Chemother. 41:2310-2311.
13. Liendo, A., K. Lazardi, and J. A. Urbina. 1998. Antiproliferative effects and mechanism of action of D0870 and its S(-) enantiomer against Trypanosoma cruzi. J. Antimicrob. Chemother. 41:197-205.
14. Lozano-Chiu, M., S. Rikan, V. L. Paetznick, E. J. Anaissie, D. Loebenberg, and J. H. Rex. 1999. Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother. 43:589-591.
15. Lutz, J. E., K. V. Clemons, B. H. Aristizabal, and D. A. Stevens. 1997. Activity of the triazole SCH 56592 against disseminated murine coccidiodomycosis. Antimicrob. Agents Chemother. 41:1558-1561.
16. Maldonado, R. A., J. Molina, G. Payares, and J. A. Urbina. 1993. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas disease. Antimicrob. Agents Chemother. 37: 1353-1359.
17. Martins-Filho, O., M. E. S. Pereira, J. S. Carvalho, J. R. Cançado, and Z. Brener. 1995. Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease. Clin. Diagn. Lab. Immunol. 2:569-573.
18. McCabe, R. E. 1988. Failure of ketoconazole to cure chronic murine Chagas disease. J. Infect. Dis. 158:1408-1409.
19. Michailowsky, V., S. M. F. Murta, L. Carvalho-Oliveira, M. E. S. Pereira, L. R. P. Ferreira, Z. Brener, A. J. Romanha, and R. T. Gazzinelli. 1998. Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi. Antimicrob. Agents Chemother. 42:2549-2556.
20. Moreira, A. A. B., H. B. W. T. DeSouza, V. Amato Neto, L. Matsubara, P. L. S. Pinto, J. E. Tolezano, E. V. Nunes, and M. Okumura. 1992. Avaliacão da atividade terapêutica do itraconazol nas infecçoes crônicas, experimental e humana, pelo Trypanosoma cruzi. Rev. Inst. Med. Trop. Sao Paulo 34:177-180.
21. Oakley, K. L., G. Morrisey, and D. W. Denning. 1997. Efficacy of SCH 56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1504-1507.
22. Perfect, J. R., G. M. Cox, R. K. Dodge, and W. A. Schell. 1996. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40:1910-1913.
23. Pfaller, M. A., S. A. Messer, and R. N. Jones. 1997. Activity of a new triazole, SCH 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 41:233-235.
24. Quintas, L. E. M., S. L. de Castro, J. A. Urbina, J. A. Borba-Santos, C. N. Pinto, R. Siqueira-Batista, and N. Miranda Filho. 1996. Tratamento da doença de Chagas, p. 125-170. In R. Siqueira-Batista, A. D. Corrêa, and D. W. Higgins (ed.), Molestia de Chagas. Editora Cultura Medica, Rio de Janeiro, Brazil.
25. Quintas, L. E. M., and R. Siqueira-Batista. 1996. Inmunologia, p. 53-74. In R. Siqueira-Batista, A D. Corrêa, and D. W. Huggins (ed.), Molestia de Chagas. Editora Cultura Medica, Rio de Janeiro, Brazil.
26. Rassi, A., and A. O. Luquetti. 1992. Therapy of Chagas disease, p. 237-247. In S. Wendel, Z. Brener, M. E. Camargo, and A. Rassi (ed.), Chagas disease (American trypanosomiasis): its impact on transfusion and clinical medicine. ISBT Brazil'92, São Paulo, Brazil.
27. Rocha, A., A. C. O. Menezes, A. M. Silva, M. S. Ferreira, S. A. Nishioka, M. K. N. Burgarelli, E. Almeida, G. Turcato, Jr., K. Metze, and E. R. Lopes. 1994. Pathology of patients with Chagas' disease and acquired immunodeficiency syndrome. Am. J. Trop. Med. Hyg. 50:261-268.
28. Sugar, A. M., and X.-P. Liu. 1996. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob. Agents Chemother. 40:1314-1316.
29. Urbina, J. A. 1997. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 117:S91-S99.
30. Urbina, J. A. 1999. Chemotherapy of Chagas' disease: the how and the why. J. Mol. Med. 77:332-338.
31. Urbina, J. A., K. Lazardi, T. Aguirre, M. M. Piras, and R. Piras. 1988. Antiproliferative synergism of the allylamine SF-86327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother. 32:1237-1242.
32. Urbina, J. A., K. Lazardi, E. Marchan, G. Visbal, T. Aguirre, M. M. Piras, R. Piras, R. A. Maldonado, G. Payares, and W. De Souza. 1993. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vivo and in vitro studies. Antimicrob. Agents Chemother. 37:580-591.
33. Urbina, J. A., G. Payares, L. M. Contreras, A. Liendo, C. Sanoja, J. Molina, M. Piras, R. Piras, N. Perez, P. Wincker, and D. Loebenberg. 1998. Anti-proliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob. Agents Chemother. 42:1771-1777.
34. Urbina, J. A., G. Payares, J. Molina, C. Sanoja, A. Liendo, K. Lazardi, M. M. Piras, R. Piras, N. Perez, P. Wincker, and J. F. Ryley. 1996. Cure of short- and long-term experimental Chagas disease using D0870. Science 273:969-971.
35. 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Chemotherapy 42:294-307.
36. 24(25)-sterol methyl transferase inhibitors and their combinations with ketoconazole. Mol. Biochem. Parasitol. 73:199-210.